Standardizing Immune-Related AE Management in Global Oncology Trials 

August 4th, 2026
11 a.m. EDT

Immunotherapy has transformed the oncology treatment landscape, offering more targeted and durable approaches across a growing range of malignancies. However, unlike traditional cancer treatments, immune-based therapies introduce a unique spectrum of immune-related adverse events (irAEs) that can significantly impact patient safety, trial continuity, and overall program success if not managed effectively.

In this webinar, you will learn practical strategies for adverse event management in oncology clinical trials, with a focus on immune-based therapies. The expert speakers will discuss the importance of cross-functional collaboration among sponsors, medical monitors, and investigative sites; the role of standardized irAE grading and management guidelines; and how technology and site training can improve consistency, patient retention, and site confidence.

Join us to gain actionable insights into how proactive irAE management can help protect promising oncology assets while supporting safer, more efficient trial execution.

Attendees will gain insights into:

• Efficient cross-functional coordination to support successful ir-AE management
• Standardized approaches to ir-AE guidelines and grading
• How improved ir-AE management can lead to better patient safety and retention

Sources:

J Clin Oncol 44, 2026 (suppl 16; abstr e23311)

Speakers:

Gwyn Bebb, M.D., Ph.D. – SVP, Head of Medical Affairs and Medical Oncology Strategy Lead

Salini Naidu, M.D. – Senior Medical Director III, Medical Oncology and Oncology Strategy, Medical Affairs